Abstract
The evolution of thalidomide as an effective treatment in several neoplasms has led to the search for compounds with increased antiangiogenic and anti-tumor effects, but decreased side-effects. The development of thalidomide analogues which retain the immunomodulatory effects of the parent compound, while minimizing the adverse reactions, brought about a class of agents termed the Immunomodulatory drugs (IMiDs). The IMiDs have undergone significant advances in recent years as evidenced by the recent FDAapprovals of one of the lead compounds, CC-5013 (lenalidomide), for 5q- myelodysplasia and for multiple myeloma (MM). Actimid (CC-4047), another IMiD lead compound, has also undergone clinical testing in MM. Apart from hematologic malignancies, these drugs are actively under investigation in solid tumor malignancies including prostate cancer, melanoma, and gliomas, in which potent activity has been demonstrated. The preclinical and clinical data relating to these analogues, as well as ENMD-0995, are reviewed herein. Encouraging results with these thalidomide analogues brought forth synthesis and screening of additional novel thalidomide analogues in the N-substituted and tetrafluorinated classes, including CPS11 and CPS49. This review also discusses the patents and preclinical findings for these agents.
Keywords: Thalidomide analogues, CC-5013, Lenalidomide, CC-4047, CPS49, CPS11, Multiple Myeloma, Prostate cancer
Recent Patents on Anti-Cancer Drug Discovery
Title: Thalidomide Analogues as Anticancer Drugs
Volume: 2 Issue: 2
Author(s): Jeanny B. Aragon-Ching, Haiqing Li, Erin R. Gardner and William D. Figg
Affiliation:
Keywords: Thalidomide analogues, CC-5013, Lenalidomide, CC-4047, CPS49, CPS11, Multiple Myeloma, Prostate cancer
Abstract: The evolution of thalidomide as an effective treatment in several neoplasms has led to the search for compounds with increased antiangiogenic and anti-tumor effects, but decreased side-effects. The development of thalidomide analogues which retain the immunomodulatory effects of the parent compound, while minimizing the adverse reactions, brought about a class of agents termed the Immunomodulatory drugs (IMiDs). The IMiDs have undergone significant advances in recent years as evidenced by the recent FDAapprovals of one of the lead compounds, CC-5013 (lenalidomide), for 5q- myelodysplasia and for multiple myeloma (MM). Actimid (CC-4047), another IMiD lead compound, has also undergone clinical testing in MM. Apart from hematologic malignancies, these drugs are actively under investigation in solid tumor malignancies including prostate cancer, melanoma, and gliomas, in which potent activity has been demonstrated. The preclinical and clinical data relating to these analogues, as well as ENMD-0995, are reviewed herein. Encouraging results with these thalidomide analogues brought forth synthesis and screening of additional novel thalidomide analogues in the N-substituted and tetrafluorinated classes, including CPS11 and CPS49. This review also discusses the patents and preclinical findings for these agents.
Export Options
About this article
Cite this article as:
Jeanny B. Aragon-Ching , Haiqing Li , Erin R. Gardner and William D. Figg , Thalidomide Analogues as Anticancer Drugs, Recent Patents on Anti-Cancer Drug Discovery 2007; 2 (2) . https://dx.doi.org/10.2174/157489207780832478
DOI https://dx.doi.org/10.2174/157489207780832478 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Characterization of Cancer Stem Cells and Primary Cilia in Medulloblastoma
CNS & Neurological Disorders - Drug Targets Fluorescence Imaging in Cancerology
Current Molecular Imaging (Discontinued) Experimental Models for Evaluation of Nanoparticles in Cancer Therapy
Mini-Reviews in Medicinal Chemistry Tissue Biomarkers for Prostate Cancer Radiation Therapy
Current Molecular Medicine Graphical Abstracts
Letters in Drug Design & Discovery The Blood-Brain/Tumor Barriers: Challenges and Chances for Malignant Gliomas Targeted Drug Delivery
Current Pharmaceutical Biotechnology Gene Therapy Targeting Nuclear Factor-κB: Towards Clinical Application in Inflammatory Diseases and Cancer
Current Gene Therapy Patents on Brain Permeable Nanoparticles
Recent Patents on CNS Drug Discovery (Discontinued) Peptide-based Radiopharmaceuticals for Targeted Tumor Therapy
Current Medicinal Chemistry Functions of Polo-Like Kinases: A Journey From Yeast To Humans
Protein & Peptide Letters The Golden Spice for Life: Turmeric with the Pharmacological Benefits of Curcuminoids Components, Including Curcumin, Bisdemethoxycurcumin, and Demethoxycurcumins
Current Organic Synthesis Protein Degradation by the Ubiquitin-Proteasome Pathway and Organ Fibrosis
Current Medicinal Chemistry A Review of the Biological Activities of Heterocyclic Compounds Comprising Oxadiazole Moieties
Current Topics in Medicinal Chemistry Targeting of Metabotropic Glutamate Receptors for the Treatment of Schizophrenia
Current Pharmaceutical Design Functional Cross-Talk between Adenosine and Metabotropic Glutamate Receptors
Current Neuropharmacology Nanostructures for Bypassing Blood Brain Barrier
Current Bioactive Compounds CD26/Dipeptidyl Peptidase IV as a Novel Therapeutic Target for Cancer and Immune Disorders
Mini-Reviews in Medicinal Chemistry Na, K-ATPase as a Biological Target for Gold(III) Complexes: A Theoretical and Experimental Approach
Current Medicinal Chemistry The Arrestin Fold: Variations on a Theme
Current Genomics Monoclonal Antibodies as Cancer Therapeutics
Recent Patents on Biotechnology